Influenza and Bacterial Coinfection in Adults With Community-Acquired Pneumonia Admitted to Conventional Wards: Risk Factors, Clinical Features, and Outcomes by Abelenda Alonso, Gabriela et al.
M A J O R  A R T I C L E
 Risk Factors, Clinical Features, and Outcomes • ofid • 1
Open Forum Infectious Diseases
 
Received 20 November 2019; editorial decision 20 February 2020; accepted 25 February 2020.
Presented in part: 23rd Congress of the Spanish Society of Infectious Diseases and Clinical 
Microbiology (SEIMC), 23 May 2019, Madrid, Spain.
Correspondence: Carlota Gudiol, MD, PhD, Department of Infectious Diseases, Bellvitge 
University Hospital, Feixa llarga s/n 08907, L’Hospitalet de Llobregat, Barcelona, Spain 
(carlotagudiol@gmail.com).
Open Forum Infectious Diseases®
© The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases 
Society of America. This is an Open Access article distributed under the terms of the Creative 
Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/
by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any 
medium, provided the original work is not altered or transformed in any way, and that the 
work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
DOI: 10.1093/ofid/ofaa066
Influenza and Bacterial Coinfection in Adults With 
Community-Acquired Pneumonia Admitted to 
Conventional Wards: Risk Factors, Clinical Features, and 
Outcomes
Gabriela Abelenda-Alonso,1,2,3 Alexander Rombauts,1,2,3 Carlota Gudiol,1,2,3,4 Yolanda Meije,5 Lucía Ortega,5 Mercedes Clemente,5 Carmen Ardanuy,6,   
Jordi Niubó,6 and Jordi Carratalà1,2,3,4
1Department of Infectious Diseases, Hospital Universitari de Bellvitge, Barcelona, Spain, 2Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona, Spain, 3University of Barcelona, 
Barcelona, Spain, 4Spanish Network for Research in Infectious Diseases, Instituto de Salud Carlos III, Madrid, Spain, 5Department Internal Medicine, Infectious Diseases Unit, Hospital de 
Barcelona, Societat, Cooperativa d’Installacions Assistencials Sanitàries (SCIAS), Barcelona, Spain, 6Department Clinical Microbiology, Hospital Universitari de Bellvitge, Barcelona, Spain
Background. Relevance of viral and bacterial coinfection (VBC) in non-intensive care unit (ICU) hospitalized adults with 
community-acquired pneumonia (CAP) is poorly characterized. We aim to determine risk factors, features, and outcomes of VBC-
CAP in this setting.
Methods. This is a prospective cohort of adults admitted to conventional wards with CAP. Patients were divided into VBC-CAP, 
viral CAP (V-CAP), and bacterial CAP (B-CAP) groups. Independent risk and prognostic factors for VBC-CAP were identified.
Results. We documented 1123 episodes: 57 (5.1%) VBC-CAP, 98 (8.7%) V-CAP, and 968 (86.1%) B-CAP. Patients with VBC-
CAP were younger than those with B-CAP (54 vs 71 years; P < .001). Chronic respiratory disease was more frequent in patients with 
VBC-CAP than in those with V-CAP (26.3% vs 14.3%%; P = .001). Among those with influenza (n = 153), the VBC-CAP group re-
ceived empirical oseltamivir less often (56.1% vs 73.5%; P < .001). Patients with VBC-CAP also had more respiratory distress (21.1% 
VBC-CAP; 19.4% V-CAP, and 9.8% B-CAP; P < .001) and required ICU admission more often (31.6% VBC-CAP, 31.6% V-CAP, and 
12.8% B-CAP; P < .001). The 30-day case-fatality rate was 3.5% in the VBC-CAP group, 3.1% in the V-CAP group, and 6.3% in the 
B-CAP group (P = .232). Furthermore, VBC-CAP was associated with severity criteria (odds ratio [OR], 5.219; P < .001) and lack of 
empirical oseltamivir therapy in influenza cases (OR, 0.401; P < .043).
Conclusions. Viral and bacterial coinfection-CAP involved younger patients with comorbidities and with poor influenza vacci-
nation rate. Patients with VBC-CAP presented more respiratory complications and more often required ICU admission. Nevertheless, 
30-day mortality rate was low and related either to severity criteria or to delayed initiation of oseltamivir therapy.
Keywords.  clinical features; coinfection; community-acquired pneumonia; influenza virus; prognostic factors.
Community-acquired pneumonia (CAP) continues to be one 
of the main causes of morbidity and mortality worldwide [1]. 
It accounts for over 4.5 million outpatient and emergency 
room visits annually in the United States [2], leading to 24.8 
admissions per 10 000 adults per year, with higher rates in eld-
erly patients [3]. A review of 98 studies assessing the burden of 
CAP among adults in Europe found that its incidence varied 
by country, age, and gender [4]. In Spain, a population-based 
cohort study of 11 241 patients aged ≥65 years reported an inci-
dence of 14 cases per 1000 person-years [5].
The prognosis of patients with CAP also varies greatly. It is 
notable that the in-hospital 30-day mortality ranges from 4% 
to 18%, rising to 50% in patients admitted to the intensive care 
unit (ICU) [6]. Several factors other than age are associated 
with mortality, including comorbidities, frailty, cardiovascular 
complications [7], inflammatory response [8], and etiology [9]. 
Streptococcus pneumoniae also continues to be the most fre-
quently identified bacteria in patients with CAP, although the 
overall incidence of pneumococcal pneumonia appears to be 
decreasing in some institutions [10], and interestingly, respira-
tory viruses are increasingly being identified [11]. No patho-
gens are identified by traditional microbiological analysis in 
up to 62% of cases [12]. With the advent of multiple molecular 
detection tests, the detection of viral and bacterial coinfection 
(VBC) in CAP has increased. In a prospective study of 49 
adults admitted to ICUs with CAP, 39% of those in whom viral 
Summary 
In this study of adults with CAP admitted to conventional wards, we assessed the rate of VBC. This potentially distinct CAP classification presented 
more often in younger patients with poorer influenza vaccine coverage and was associated with worse clinical outcomes.
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polymerase chain reaction (PCR) techniques were applied had 
VBC [13]. However, the role of VBC is controversial because 
the presence of bacteria in the airway can lead to viral repli-
cation and vice versa [14]. In addition, up to 38% of healthy 
people who tested positive for influenza viruses in nasal epithe-
lium do not develop disease [15].
The role of VBC in CAP has been analyzed in some reports, 
but many of these have had important limitations. Some have 
focused on patients admitted to the ICU [13, 16, 17], and others 
have involved only pediatric patients [18], both of which can 
lead to significant bias when determining the impact of VBC on 
the overall population of patients with CAP. In other research, 
severely immunocompromised patients have been included, 
which risks significant host-dependent bias in potential severity 
[19]. Moreover, the etiology of CAP may be different in immu-
nocompromised hosts, with the results of a large multicenter 
study by Di Pasquale et  al [20] reporting that these patients 
more often had a viral etiology.
Given the limitations of existing research, the relevance of 
VBC in immunocompetent adults hospitalized to non-ICU 
setting with CAP remains poorly characterized. Therefore, in 
the present study, we aim to determine risk factors, clinical 
features, and outcomes of VBC-CAP in adults without severe 
immunocompromise who are admitted to conventional wards.
METHODS
Study Design, Setting, and Participants
The study consisted of a prospective cohort that was not 
originally designed to perform this analysis of patients ad-
mitted to 2 tertiary hospitals in Barcelona, Spain: Hospital 
Universitari de Bellvitge and SCIAS-Hospital de Barcelona. 
Hospital Universitari de Bellvitge is a referral public center for 
Southern Hospitalet and El Prat de Llobregat. SCIAS-Hospital 
de Barcelona is a private center, which does not cover a spe-
cific geographical area. Furthermore, the 2 centers are located 
in different parts of Barcelona. The study was approved by the 
Ethics Committee of the coordinating center as Spanish legisla-
tion requires, and the procedures followed were in accordance 
with the ethical standards of the Helsinki Declaration. Due to 
the retrospective analysis of the prospectively observational col-
lected data, written informed consent was waived by the local 
Ethics Committee.
We included all immunocompetent adults (age >18 years old) 
initially admitted to conventional medical wards with a radio-
logically and microbiologically confirmed diagnosis of CAP be-
tween January 2009 and December 2016. Immunocompromised 
patients such as those with human immunodeficiency virus in-
fection, active malignancy, or receiving any immunosuppres-
sant drug were excluded from the study. Approximately half of 
the patients were included during the winter season. Patients 
admitted to the hospital with the diagnosis of pneumonia were 
identified from a hospital admissions’ list by the research team 
during the first 48 hours from admission. For analysis, we di-
vided patients with CAP into 3 groups according to their eti-
ology: VBC-CAP, viral CAP (V-CAP), and bacterial CAP 
(B-CAP).
Clinical Assessment
There was no standardization of the microbiological studies, 
hospital admission criteria, or treatment decisions, which 
were instead at the discretion of attending physicians, thereby 
replicating real-world practice. Patients were seen during their 
hospital stays by 1 or more of the investigators, and their data 
were recorded with the aid of a standardized computer-based 
protocol. To stratify patients with pneumonia according by 
prognosis, the pneumonia severity index, Simplified Acute 
Physiology Score, and CURB-65 score were determined.
Definitions
Pneumonia was defined as the presence of a new infiltrate on 
a chest radiograph plus fever (temperature ≥38°C) and/or res-
piratory symptoms including dyspnea, chest pain, and produc-
tive cough. Pneumonia due to coinfection (VBC-CAP) was 
diagnosed in patients presenting a positive viral PCR test and 
evidence of bacterial infection by blood culture, Gram stain 
and sputum culture, pleural effusion culture, or urinary an-
tigen for S pneumoniae and Legionella pneumophila. Primary 
viral pneumonia (V-CAP) was diagnosed in patients presenting 
pneumonia with negative respiratory and blood cultures for 
bacteria and with negative urinary antigen tests and positive 
viral PCR from a nasopharyngeal swab. Bacterial pneumonia 
(B-CAP) was diagnosed in patients with ≥1 positive culture 
(blood, Gram stain and sputum, pleural aspirate, or urinary 
antigen). The absence of PCR viral diagnostic test was not an 
exclusion criterion to the B-CAP group. An etiologic diagnosis 
was considered definitive in the following situations: positive 
viral PCR from a nasopharyngeal swab, isolation of a respi-
ratory pathogen in a usually sterile specimen, isolation of L 
pneumophila in sputum, detection of L pneumophila serogroup 
1 or pneumococcal antigen in the urine, a 4-fold increase in 
the antibody titer, or seroconversion for atypical pathogens. 
Presumptive aspiration pneumonia was diagnosed on a clinical 
and radiological basis in patients with risk factors (eg, com-
promised consciousness, altered gag reflex, dysphagia, severe 
periodontal diseases, putrid sputum and radiographic evidence 
of involvement of a dependent pulmonary segment, or necro-
tizing pneumonia). Cases that did not meet any of the criteria in 
this section were considered pneumonias of unknown etiology 
and were excluded. Septic shock was diagnosed when the sys-
tolic blood pressure was <90 mmHg and the patient required 
vasopressor therapy.
Vaccination status was assessed from interviews with the pa-






/ofid/article/7/3/ofaa066/5760732 by guest on 26 January 2021
 Risk Factors, Clinical Features, and Outcomes • ofid • 3
health records. A  person was considered vaccinated against 
the S pneumoniae and influenza at admission if they had been 
given a 23-valent polysaccharide pneumococcal vaccine within 
5 years or had received a seasonal influenza vaccine in the prior 
year, respectively. Comorbidities were recorded and assessed by 
the Charlson comorbidity index.
Time to clinical stability was established from admission 
with CAP to patients reaching the following objective criteria: 
oral intake capacity, absence of exacerbation of underlying dis-
eases, and stable vital signs (body temperature ≤37.8°C, res-
piratory rate ≤24 breaths/minute, and systolic blood pressure 
≥90 mmHg without vasoactive support). Complications were 
defined as any untoward events that occurred during hospi-
talization. Prehospital antibiotic treatment was defined as the 
oral intake of antimicrobials prescribed >24 hours for the acute 
episode. Empirical treatment was defined as the first treatment 
received with no microbiological information. Broad-spectrum 
treatment includes carbapenem, piperacillin-tazobactam, and 
any type of antipseudomonal treatment. The in-hospital 30-day 
case-fatality rate was defined as death from any cause within 
30 days of hospital admission.
Microbiological Studies
Microbiological diagnostic techniques were performed fol-
lowing the local guidelines in all patients, and viral PCR was 
requested based on clinical suspicion. In the case of viral PCR, 
information in adults with CAP was only available in patients in 
whom the result was positive.
Viral infection was established by 2 specific multiplex 
real-time PCR devices used for typing and subtyping influ-
enza virus, as detailed in the real-time RT-PCR Protocol for 
Detection and Characterization of Influenza A  supplied by 
the Centers for Disease Control and Prevention (Atlanta, GA) 
[21]. Human respiratory syncytial respiratory virus and human 
metapneumovirus (hMPV) were also detected using 2 specific 
multiplex real-time PCR devices [22].
The investigation of bacterial pathogens in blood, sputum, 
and other samples was performed by standard microbi-
ologic procedures within the first 48 hours after admis-
sion. We detected S pneumoniae antigen in urine by rapid 
immunochromatographic assay (NOW Assay; Binax Inc., 
Portland, ME) or enzyme-like immunosorbent assay (ELISA-
Bartels, Wicklow, Ireland) and L pneumophila serogroup 1 an-
tigen by an immunochromatographic method (NOW Legionella 
Urinary Antigen; Binax Inc.). Standard serologic methods were 
used to determine antibodies against atypical bacteria.
Statistical Analysis
Descriptive statistical analysis was performed for all study vari-
ables, with proportions calculated as percentages of patients 
with available data. We compared patients among the VBC-
CAP, V- CAP, and B-CAP groups. The Kolmogorov-Smirnoff 
test was used to check for normality. Significant differences 
were then tested using the × 2 test between qualitative variables 
and the Student’s t distribution or Mann-Whitney U test be-
tween quantitative variables. To determine the factors poten-
tially associated with developing VBC-CAP, compared with 
V-CAP and B-CAP, we performed a multivariate analysis by 
multinomial logistic regression for variables with statistical sig-
nificance in the univariate analysis. Severity variables (ie, ICU 
admission, mechanical ventilation, shock, and vasoactive drug 
use) were grouped together based on multicollinearity (the cor-
relation coefficient was >0.6).
RESULTS
Patient Characteristics and Clinical Features
We assessed a total of 1916 patients during the study period, and 
after excluding those without a documented microbiological di-
agnosis, 1123 were finally evaluated. This cohort comprised 57 
cases of VBC-CAP (5.07%), 98 cases of V-CAP (8.72%), and 
968 cases of B-CAP (86.16%). Of note, coinfection accounted 
for only 36.77% of cases among patients with pneumonia and 
viral involvement. The demographic and clinical characteristics 
of the 3 groups are shown in Tables 1 and 2. The median age of 
patients with VBC-CAP was similar to that of the V-CAP group, 
but it was significantly lower than that of the B-CAP group 
(P < .001). However, comorbidities, particularly chronic res-
piratory diseases, were more frequent in the VBC-CAP group 
than in the V-CAP group (P = .001). Furthermore, the rate of 
seasonal influenza vaccination was significantly lower in the 
VBC-CAP group compared with the B-CAP group (P < .001).
Symptom onset was shorter in the VBC-CAP group than 
in the V-CAP group (P = .017), and patients were more 
likely to present with purulent sputum (P = .008) and cough 
(P < .001), whereas myalgia was more frequent in the VBC-
CAP group than in the B-CAP group (P < .001). It is inter-
esting to note that the VBC-CAP group received prehospital 
antibiotics less often than the V-CAP and B-CAP groups 
(P < .001). Although all severity scores were significantly 
higher in the B-CAP group, bilateral pulmonary involve-
ment and septic shock at presentation were significantly more 
common in the VBC-CAP group.
Microbiological Results
Table  3 summarizes the viral and bacterial etiologies. Blood 
culture was performed in 86.16% of patients, sputum culture 
was performed in 65.29%, S pneumoniae urine antigen test was 
performed in 89.19%, Legionella spp urine antigen test was per-
formed in 58.82%, and serology for atypical pathogens was per-
formed in 43.78%. There were no significant differences in the 
number of diagnostic tests performed in the 2 centers or among 
study groups, except for atypical pathogens serology: 68.42% 
was performed in the VBC-CAP group, 68.36% was performed 
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patients. As shown, S pneumoniae was the most frequently docu-
mented bacteria in the VBC-CAP (80.70%) and B-CAP (63.22%) 
group. Influenza A H1N1 was the most frequently documented 
virus in the VBC-CAP (66.66%) and V-CAP (85.70%) groups. 
Coinfection due to S pneumoniae and influenza A  H1N1 was 
present in 54.38% of cases in the VBC-CAP group. Most patients 
in this group presented with an influenza A virus (82.2%), none 
had coinfection with gram-negative bacilli and Staphylococcus 
aureus isolation in this group was scarce (7.01%).
Antibiotic Treatment and Clinical Outcomes
Data regarding antibiotic treatment and clinical outcomes in the 
different study groups are summarized in Table 4. It is notable 
that the VBC-CAP group received empirical treatment with 
oseltamivir less frequently than the V-CAP group (P <  .001), 
with most patients receiving empirical combination therapy. 
This typically comprised a beta-lactam plus a fluoroquinolone, 
especially in VBC-CAP group (P = .001). Fluoroquinolone 
monotherapy was used significantly more often in the V-CAP 
group (P < .001). Intensive care unit admission (P < .001) and 
mechanical ventilation (P  <  .001) were required significantly 
more often for patients with VBC-CAP-C and V-CAP. Overall, 
the 30-day case-fatality rate was similar in all groups, with a 
trend toward a higher frequency in the B-CAP group (P = .232).
Factors Associated With Coinfection
Table 5 shows that factors that were associated with coinfection. 
Lack of prehospital antibiotic administration, purulent sputum, 
and lack of empirical oseltamivir therapy were independent 
risk factors for VBC-CAP when compared with the V-CAP 
and B-CAP groups. Compared with the B-CAP group, severity 
criteria were more likely to be present in the VBC-CAP group 
(OR, 5.219; P < .001) and showed a trend to being more likely 
in the V-CAP group (OR, 2.715; P = .060).
DISCUSSION
To date, few studies have assessed the clinical features and out-
comes of VBC-CAP in immunocompetent adults admitted to 
conventional medical wards [23, 24]. Most studies addressing 
VBC have analyzed different clinical presentations of respira-
tory viral infection together and have included patients without 
pneumonia [25, 26]. In addition, the majority have been per-
formed in ICU settings [16, 17, 27]. Although VBC was first de-
scribed at the beginning of the 20th century during an influenza 
pandemia [28], it was only during the pandemic of 2009 that 
VBC was highlighted as a complication of V-CAP. The recent 
introduction of comprehensive molecular tests for diagnosing 
adults with CAP could help to demonstrate VBC-CAP as a sep-
arate diagnostic category [29].
In our large cohort of patients with CAP, we found an overall 
low percentage with VBC-CAP. Nevertheless, when analyzing 
the sum of patients with viral infection, the rate of coinfection 
varied significantly from 5.07% to 36%, and it was higher than 
reported in previous studies of patients with influenza pneu-
monia [30]. Patients with VBC-CAP were significantly younger 
Table 1. Baseline Characteristics
Characteristics VBC-CAP (n = 57) V-CAP (n = 98) B-CAP (n = 968) P Value
Age (years, media, IQR) 54 (42.50–69.50) 55 (42.75–70) 71 (56–80) <.001
Male sex 39 (68.42%a) 56 (54.36%) 633 (65.4%) .224
Charlson index (IQR) 2 (0–3) 2 (1–3) 3 (1–4) .062
Comorbidities 32 (56.1%) 54 (55.1%) 760 (78.5%) <.001
 Chronic respiratory disease 15 (26.3%) 14 (14.3%) 309 (31.9%) .001
 Diabetes mellitus 9 (15.8%) 20 (20.4%) 220 (22.7%) .428
 Chronic cardiac failure 8 (14%) 21 (21.4%) 237 (24.5%) .168
 Malignancy 3 (5.3%) 5 (5.1%) 111 (11.5%) .061
 Chronic kidney diseaseb 6 (10.5%) 10 (10.2%) 135 (13.9%) .470
 Chronic liver diseasec 6 (10.5%) 6 (6.1%) 95 (9.8%) .478
 Cerebrovascular disease 2 (3.5%) 6 (6.1%) 102 (10.5%) .098
 Dementia 2 (3.5%) 5 (5.1%) 92 (9.5%) .119
Corticosteroids 3 (5.4%) 10 (11%) 58 (6.3%) .210
Immunosuppressors 8 (14.3%) 12 (13.2%) 114 (12.3%) .894
Chemotherapy 1 (1.8%) 1 (1.1%) 12 (1.3%) .937
HIV 2 (3.6%) 3 (3.3%) 47 (5.1%) .675
Prehospital antibiotics 2 (3.5%) 29 (29.6%) 164 (17%) <.001
Influenza vaccine (season) 16 (30%) 23 (26.7%) 483 (53.3%) <.001
Pneumococcal vaccine (≤5 years) 10 (19.2%) 12 (14.10%) 187 (21.7%) .251
Abbreviations: B-CAP, bacterial community-acquired pneumonia; HIV, human immunodeficiency virus; IQR, interquartile range; V-CAP, viral CAP; VBC-CAP, viral and bacterial coinfection CAP.
aProportions were calculated as percentages of patients with available data.
bIncludes patients with mild and moderate and severe chronic renal disease according to Charlson comorbidity index.
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than those with B-CAP, but they each presented with similar 
rates of chronic respiratory disease. Of note, patients with VBC-
CAP had a low rate of vaccination for seasonal influenza. These 
findings may reflect the previous report that seasonal influenza 
vaccine coverage may be lower in patients with chronic under-
lying conditions than in older patients [31]. However, perhaps 
of greatest note, we found that patients with VBC-CAP re-
ceived antibiotics less often before admission than patients with 
B-CAP. This is remarkable given that clinical manifestations 
were similar in both groups, including cardinal findings such 
as purulent sputum and lobar infiltrates. These findings could 
be related to an overall low index of suspicion of coinfection, 
particularly out of the flu season.
As reported by other investigators [32], patients with VBC-
CAP presented in respiratory failure at admission more often 
than patients with B-CAP. In this scenario, severity scores might 
not help to assess the potential risk of poor outcomes because 
they rely mostly on age and the presence of comorbidities [33]. 
Patients with VBC-CAP also received empirical oseltamivir 
therapy less frequently than those with V-CAP, which is highly 
relevant given that a delay in antiviral treatment has been asso-
ciated with poor outcomes in V-CAP [34, 35]. Of note, as re-
cently addressed in the Infectious Diseases Society of America/
American Thoracic Society guidelines [36], there have been no 
clinical trials evaluating the impact of antiviral treatment in pa-
tients with VBC-CAP.
As previously reported, we confirmed that coinfection was 
mainly caused by influenza A  virus and S pneumoniae [32]. 
However, we found that the rate of coinfection with S aureus 
was lower. This could be explained by geographical differences 
in CAP etiology [37] and by the observation that S aureus 
coinfection is mostly observed in ICU settings [38].
As is expected to a cohort initially admitted to conven-
tional medical wards, case-fatality rate was low. Despite 
the fact that we did not find a significant difference among 
groups, patients with V-CAP and VBC-CAP presented 
less mortality than B-CAP patients. This fact probably re-
flected the older age and high frequency of comorbidities 
in the B-CAP group, which could have limited ICU ad-
missions. Nevertheless, VBC-CAP did present with more 
Table 2. Clinical Characteristicsa
Characteristics VBC-CAP (n = 57) V-CAP (n = 98) B-CAP (n = 968) P Value
Days from onset of symptoms to admission (median, IQR) 4 (3–7) 5 (3–7) 4 (2–7) .017
Clinical Manifestations     
 Axillary temperature ≥38ºC 31 (54.4%) 54 (55.1%) 757 (43.0%) .017
 Previous URTI 15 (26.3%) 35 (35.7%) 294 (30.5%) .766
 Chills 21 (36.8%) 29 (29.6%) 368 (38.1%) .249
 Diarrhea/vomiting 7 (12.3%) 25 (25.5%) 202 (20.9%) .148
 Cough 56 (98.2%) 95 (96.9%) 833 (86.1%) <.001
 Purulent sputum 36 (63.20%) 34 (37%) 435 (46.7%) .008
 Chest pain 15 (26.3%) 15 (15.3%) 351 (36.3%) <.001
 Dyspnea 40 (70.20%) 73 (74.5%) 660 (68.2%) .427
 Headache 7 (12.30%) 17 (17.3%) 136 (14.0%) .612
 Myalgia 29 (50.9%) 54 (55.10%) 176 (18.2%) <.001
 Confusion 3 (5.3%) 5 (5.1%) 170 (17.6%) <.001
 Septic shock at presentation 6 (10.5%) 7 (12.1%) 63 (9.1%) .028
Radiological Findings     
 Multilobular involvement 3 (5.3%) 7 (7.1%) 222 (12.6%) .047
 Bilateral pulmonary infiltrates 20 (35.1%) 31 (31.6%) 363 (20.6%) <.001
 Interstitial pattern 5 (8.8%) 32 (32.7%) 31 (1.8%) <.001
 Unilobular pulmonary infiltrates 28 (49%) 28 (28.6%) 1159 (65.8%) <.001
 Pleural effusion 8 (14%) 7 (7.2%) 277 (15.7%) .073
Laboratory Findings     
 Respiratory insufficiency 38 (67.9%) 58 (63.73%) 504 (59.7%) .163
 Leukocytes (×109/L) 9.6 (5.55–14.95) 7.0 (4.7–10.92) 12.8 (9.15–18.10) <.001
 Neutrophils (×109/L) 83.6% (78.75–88.25%) 81.55% (72.55–86.97) 84% (77.4%–88%) .018
 SAPS ≥6 11 (19.3%) 15 (15.3%) 306 (31.6%) .001
 PSI score ≥4 23 (40.4%) 40 (40.8%) 651 (67.3%) <.001
 CURB-65 score ≥2 25 (43.9%) 42 (42.9%) 675 (69.7%) <.001
Abbreviations: B-CAP, bacterial community-acquired pneumonia; IQR, interquartile range; PSI, pneumonia severity index for adult; SAPS, simplified acute physiology score; URTI, upper 
respiratory tract infection; V-CAP, viral CAP; VBC-CAP, viral and bacterial coinfection CAP. 
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severity criteria and respiratory distress than V-CAP. This 
is consistent with research showing that the host-pathogen 
interaction in VBC-CAP leads to an exposition of the al-
veoli membrane, an inability of the respiratory epithelium 
to repair itself [39], and a potent cytokine reaction, which 
combine to induce respiratory distress [40].
This study has some limitations that should be acknowledged. 
It should be noted that it was a prospective cohort that was not 
Table 4. Empirical Antimicrobial Therapy and Outcomesa
Therapy and outcomes VBC-CAP (n = 57) V-CAP (n = 98) B-CAP (n = 968) P Value
Time to antimicrobial therapy initiation (hours, IQR) 4 (3–6) 5 (3–7) 4 (3–6) .885
Empirical Antibiotic Therapy     
Beta-lactam monotherapy 8 (14.03%) 8 (8.16%) 32 (34.97%) <.001
Beta-lactam + fluoroquinolone 31 (54.38%) 45 (45.91%) 431 (44.52%) <.001
Fluoroquinolone 8 (14.03%) 30 (30.61%) 56 (5.78%) <.001
Beta-lactam + macrolide 1 (1.75%) 1 (1.02%) 34 (3.51%) <.001
Macrolide monotherapy 0 0 1 (0.1%) .921
Broad-spectrum antibiotics 2 (3.51%) 6 (6.12%) 68 (7.02%) .534
Others 1 (1.75%) 3 (3.06%) 41 (4.23%) .281
Empirical oseltamivir therapy 32 (56.12%) 72 (73.56%) 71 (3.63%) <.001
Antibiotic de-escalation 35 (61.4%) 57 (58.2%) 171 (65.7%) .283
Complications 17 (29.8%) 30 (30.6%) 267 (27.6%) .956
Respiratory distress 12 (21.10%) 19 (19.4%) 91 (9.4%) <.001
Pleural effusion 3 (5.3%) 4 (4.1%) 57 (5.9%) .755
Nosocomial infection 2 (3.5%) 8 (8.2%) 23 (1.7%) .005
Acute cardiac event 3 (5.3%) 14 (14.3%) 95 (9.8%) .177
Confusion 1 (1.8%) 5 (5.1%) 32 (3.3%) .505
Renal failure 5 (8.8%) 2 (2%) 47 (4.9%) .165
Acute hepatitis 0 0 11 (1.1%) .411
Septic shock 5 (8.8%) 5 (5.1%) 44 (4.6%) .349
ICU admission 18 (31.6%) 31 (31.6%) 171 (12.8%) <.001
Mechanical ventilation 11 (19.3%) 13 (13.4%) 69 (3.1%) <.001
Time to clinical stability (days, IQR) 5 (2–11.5) 5 (2–9) 4 (2–7) .870
Relapse 1 (1.8%) 4 (4.4%) 37 (4%) .687
30-day case-fatality rate 2 (3.5%) 3 (3.1%) 101 (6.3%) .232
Abbreviations: B-CAP, bacterial community-acquired pneumonia; ICU, intensive care unit; IQR, interquartile range; V-CAP, viral CAP; VBC-CAP, viral and bacterial coinfection CAP.
aProportions were calculated as percentages of patients with available data.
Table 3. Etiology in 1123 Cases of CAPa
Etiology VBC-CAP (n = 57) V-CAP (n = 98) B-CAP (n = 968)
Streptococcus pneumoniae 46 (80.70%) – 612 (63.22%)
Haemophilus influenzae 5 (8.77%) – 73 (7.6%)
Staphylococcus aureus 4 (7.01%) – 21 (2.2%)
Chlamydophila pneumoniae 1 (1.75%) – 40 (4.1%)
Moraxella catarrhalis 1 (1.75%) – 13 (1.3%)
Legionella spp 0 – 48 (5%)
Coxiella burnetti 0 – 1 (0.1%)
Pseudomonas aeruginosa 0 – 36 (3.7%)
Gram-negative bacilli 0 – 17 (17.56%)
Aspiration CAP 1 (1.75%)b – 107 (11.1%)c
Influenza A H1N1 38 (66.66%) 84 (85.7%) –
Influenza A H3N2 9 (15.78%) 13 (13–3%) –
Influenza B 8 (14.03%) 1 (1%) –
Respiratory syncytial virus 2 (3.50%) 0 –
Abbreviations: B-CAP, bacterial community-acquired pneumonia; CAP, community-acquired pneumonia; V-CAP, viral CAP; VBC-CAP, viral and bacterial coinfection CAP. 
aProportions were calculated as percentages of patients with available data.
bOnly 1 case was microbiologically confirmed in VBC-CAP group: Enterobacter cloacae (n = 1).
cCases microbiologically confirmed in B-CAP group: Bacteroides spp (n = 3) Prevotella bivia (n = 4), Porphyromonas asaccharalytica (n = 2), Streptococcus anginosus group (n = 5), 
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originally designed to perform this analysis in a single geographical 
location. In addition, PCR was performed based on clinical suspi-
cion, leading to potential unidentified cases and to failure to imple-
ment comprehensive multiple PCR testing, as is usual in clinical 
practice. Moreover, PCR technique used was limited to respiratory 
syncytial virus, influenza A and B virus, and hMPV. In addition, 
Mycoplasma pneumoniae PCR was not included in the atypical 
pathogens testing. Consequently, compared with the coinfection 
rate provided by some recent studies [32], the number of patients 
included in the VBC-CAP group was small and some cases could 
have been misclassified as B-CAP group. Furthermore, this was 
not a population based study, and despite its multicenter intention, 
it was limited to 2 centers in the same city in Spain. In addition, al-
though both are tertiary centers, there is an asymmetry in recruit-
ment in favor of the larger center.
CONCLUSIONS
In conclusion, this study provides a real-world perspective of the 
relevance of VBC-CAP as a potential separate diagnostic cate-
gory in adults admitted with CAP to conventional medical wards. 
Our work also emphasizes the urgent need to improve influenza 
vaccination coverage in patients with chronic underlying dis-
eases. Randomized clinical trials are now required that use mul-
tiple PCR diagnostic tests as standard if we are to identify the true 
burden of coinfection in CAP. Such data can then be used to de-
termine appropriate empirical and definitive treatment protocols.
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